全文获取类型
收费全文 | 627篇 |
免费 | 49篇 |
国内免费 | 61篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 43篇 |
妇产科学 | 13篇 |
基础医学 | 85篇 |
口腔科学 | 17篇 |
临床医学 | 95篇 |
内科学 | 166篇 |
皮肤病学 | 14篇 |
神经病学 | 11篇 |
特种医学 | 87篇 |
外科学 | 37篇 |
综合类 | 19篇 |
预防医学 | 41篇 |
眼科学 | 4篇 |
药学 | 44篇 |
中国医学 | 2篇 |
肿瘤学 | 58篇 |
出版年
2023年 | 2篇 |
2022年 | 3篇 |
2021年 | 3篇 |
2020年 | 5篇 |
2019年 | 9篇 |
2018年 | 11篇 |
2017年 | 4篇 |
2016年 | 11篇 |
2015年 | 13篇 |
2014年 | 27篇 |
2013年 | 28篇 |
2012年 | 18篇 |
2011年 | 18篇 |
2010年 | 30篇 |
2009年 | 31篇 |
2008年 | 32篇 |
2007年 | 56篇 |
2006年 | 21篇 |
2005年 | 26篇 |
2004年 | 17篇 |
2003年 | 11篇 |
2002年 | 13篇 |
2001年 | 8篇 |
2000年 | 6篇 |
1999年 | 17篇 |
1998年 | 33篇 |
1997年 | 37篇 |
1996年 | 23篇 |
1995年 | 23篇 |
1994年 | 29篇 |
1993年 | 20篇 |
1992年 | 5篇 |
1991年 | 10篇 |
1990年 | 3篇 |
1989年 | 18篇 |
1988年 | 18篇 |
1987年 | 11篇 |
1986年 | 4篇 |
1985年 | 10篇 |
1984年 | 7篇 |
1983年 | 4篇 |
1982年 | 10篇 |
1981年 | 12篇 |
1980年 | 8篇 |
1978年 | 7篇 |
1977年 | 7篇 |
1976年 | 10篇 |
1975年 | 4篇 |
1966年 | 1篇 |
1957年 | 1篇 |
排序方式: 共有737条查询结果,搜索用时 15 毫秒
1.
Balloon dacryocystoplasty: indications and contraindications 总被引:3,自引:0,他引:3
2.
Relation between respiratory symptoms, pulmonary function and peak flow variability in adults. 总被引:2,自引:0,他引:2
下载免费PDF全文
![点击此处可从《Thorax》网站下载免费的PDF全文](/ch/ext_images/free.gif)
BACKGROUND--A study was carried out to determine whether subjects with respiratory symptoms are more likely to have impaired lung function or increased airway lability, and to quantify these relationships in a population of adults. METHODS--Data were collected from 511 participants (aged 20-70 years) from the Dutch part of the European Community Respiratory Health Survey (ECRHS). The symptoms analysed were: wheeze, dyspnoea > or = grade 3, nocturnal dyspnoea, cough and phlegm, and history of allergy. Lung function was measured by peak expiratory flow (PEF) and forced expiratory volume in one second (FEV1). PEF variability was used as an index for bronchial lability. RESULTS--Both FEV1 and PEF were decreased with increasing numbers of symptoms. Subjects with one symptom had an increased risk of having an FEV1 value of < 70% (OR = 4.2) and this risk increased with an increasing number of symptoms. Subjects with three or more symptoms had an increased risk of having a PEF value of < 70%, a diurnal variation in PEF of > 10% (both OR = 4.4), and an increased risk of high between day variation (OR = 6.6). CONCLUSIONS--Subject-reported symptoms are related to impaired lung function and to increased variability of peak flow. 相似文献
3.
Duncan WC; Illingworth PJ; Young FM; Fraser HM 《Human reproduction (Oxford, England)》1998,13(9):2532-2540
The molecular mechanisms involved in luteolysis are still unclear in the
primate. This study aimed to investigate the effect of induced luteolysis
on the ovarian luteinizing hormone (LH) receptor and the steroidogenic
enzyme, 3beta-hydroxysteroid dehydrogenase (3beta-HSD) in the marmoset
monkey. Luteolysis was induced in the mid-luteal phase either directly by
systemic prostaglandin F2alpha (PGF2alpha), or indirectly by LH withdrawal
using systemic gonadotrophin releasing hormone antagonist (GnRHant)
treatment. The LH receptor was studied by isotopic mRNA in-situ
hybridization and in-situ ligand binding and 3beta-HSD expression was
studied using isotopic mRNA in-situ hybridization and immunohistochemistry.
Induced luteolysis was associated with a reduction in the expression of LH
receptor (P < 0.0001) and 3beta-HSD mRNA, closely followed by a
reduction in the LH receptor (P < 0.05) and 3beta-HSD protein
concentrations within 24 h. There were no differences in the findings
whether luteolysis was induced with PGF2alpha or GnRHant. This study shows
that disparate mechanisms to induce luteolysis in the primate result in an
identical rapid loss of the LH receptor and 3beta-HSD. In conclusion,
induced luteolysis leads to rapid loss of the steroidogenic pathway in
luteal cells.
相似文献
4.
HM Clink 《Journal of clinical pathology》1980,33(8):799-800
5.
6.
Semen parameters and testicular pathology in men with testicular cancer and contralateral carcinoma in situ or bilateral testicular malignancies 总被引:2,自引:2,他引:2
Kliesch S; Bergmann M; Hertle L; Nieschlag E; Behre HM 《Human reproduction (Oxford, England)》1997,12(12):2830-2835
We evaluated 14 patients with bilateral testicular tumour, one-sided tumour
and contralateral carcinoma in situ (CIS) of the testis or testis tumour in
single testis with respect to their fertility. We analysed semen
parameters, serum hormones [follicle-stimulating hormone (FSH), luteinizing
hormone (LH) and testosterone], testicular sonography, testicular volumes
and testicular histology prior to further anti-cancer treatment. Ten out of
14 patients showed normal or reduced sperm concentrations, while 4/14
patients were azoospermic. Serum FSH levels showed a significant negative
correlation with sperm concentrations in patients with testicular
malignancies (r = -0.64, P = 0.025). Testicular volumes revealed a
significant positive correlation with semen parameters in patients with
testes that were affected by CIS (r = 0.733, P = 0.038). We conclude that
even bilateral testicular cancer and/or CIS do not preclude fertility and,
therefore, patients should be offered andrological investigation and
therapy, including possibly surveillance strategy or the chance for
cryopreservation of the semen prior to further treatment in order to
preserve their chances for paternity.
相似文献
7.
8.
Survey of CAG/CTG repeats in human cDNAs representing new genes: candidates for inherited neurological disorders 总被引:3,自引:2,他引:3
Neri C; Albanese V; Lebre AS; Holbert S; Saada C; Bougueleret L; Meier-Ewert S; Le Gall I; Millasseau P; Bui H; Giudicelli C; Massart C; Guillou S; Gervy P; Poullier E; Rigault P; Weissenbach J; Lennon G; Chumakov I; Dausset J; Lehrach H; Cohen D; Cann HM 《Human molecular genetics》1996,5(7):1001-1009
10.
Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors. 总被引:1,自引:0,他引:1
Diana C J Spierings Elisabeth G E de Vries Wim Timens Harry J M Groen H Marike Boezen Steven de Jong 《Clinical cancer research》2003,9(9):3397-3405
PURPOSE: Several in vitro studies have shown that non-small cell lung cancer (NSCLC) cell lines are sensitive to apoptosis induction by the recombinant human (rh) tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death ligand, indicating that rhTRAIL might become an attractive molecule for treatment of NSCLCs. To investigate the therapeutic potential of rhTRAIL, the expression of TRAIL and its apoptosis-inducing receptors DR4 and DR5 was evaluated in tumors of stage III NSCLC patients. EXPERIMENTAL DESIGN: Before treatment, tumor biopsies from locally advanced NSCLC patients were obtained by bronchoscopy. DR4, DR5, and TRAIL expression were determined immunohistochemically in 87 tumors. Patients were randomized for treatment with 60 Gy radiotherapy with or without carboplatin as radiosensitizer. RESULTS: DR4, DR5, and TRAIL were expressed in 99%, 82%, and 91% of the tumors, respectively. Seventeen percent of the samples expressed only DR4 and no DR5. In NSCLCs with squamous cell differentiation, a typical staining pattern for DR4 and DR5 was observed. Cells from the basal layer were strongly positive, and the more mature cells were less positive or negative. An inverse staining pattern was observed for TRAIL. Poorly differentiated areas showed strong staining intensity for DR4, DR5, and TRAIL. DR5-positive staining was associated with increased risk of death (odds ratio, 5.76; 95% confidence interval, 1.04-31.93; P = 0.045). CONCLUSIONS: The majority of the locally irresectable stage III NSCLCs expressed at least one of the two death receptors for TRAIL. Therefore, these death receptors may provide a target for the use of rhTRAIL as a new adjunct in the treatment of stage III NSCLC. 相似文献